Data from the Phase 3 MMY3004 (CASTOR) clinical trial show the immunotherapy daratumumab (DARZALEX®) in combination with a standard of care therapy, bortezomib (a proteasome inhibitor [PI]) and...

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that treatment with rovalpituzumab tesirine (Rova-T), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC),...

OBI Pharma, Inc., a Taiwan biotech company (TPex: 4174), today announced that Phase II/III data evaluating the clinical benefit and immunogenicity of OBI-822/OBI-821 (formerly OPT‐822/OPT-821),...

Two new studies co-authored by researchers from John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and discussed at the American Society of Clinical Oncology (ASCO) annual...

Healthcare Trust of America, Inc. (NYSE:HTA), the largest dedicated owner and operator of medical office buildings (MOBs) who provides the infrastructure for the integrated delivery of healthcare...